Many investors are now increasingly focused on the company Northwest Bio (OTCMKTS:NWBO) in anticipation of the publication of Phase 3 data in relation to its brain cancer treatment.
More importantly, there is widespread expectation that the data is going to be positive for the product and that is another factor behind the sharp focus. That being said, it appears that investors are going to need to wait for a bit longer for the publication of the data.
Last week, Northwest Bio had a shareholder meeting and at the event, the executives of the company revealed that the data is going to be released at some point in the coming months in a medical journal. Earlier in May, the company had also announced that it is currently in the middle of a quiet period and is busy reviewing the data and other aspects of the Phase 3 trial of the product.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.